Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa

NCT07278011 | Completed

• 2 other identifiers: 2025/47TÜTF-GOBAEK 2024/367
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This observational translational study aims to investigate gene and protein expression in lesional and perilesional skin of patients with Hidradenitis Suppurativa (HS) compared to controls. Skin biopsies were collected from 15 HS patients and 15 age- and sex-matched healthy controls. Gene expression of 15 selected proteins was analyzed using qRT-PCR, while protein levels of 4 targets were assessed by Western blot. The study seeks to identify molecular pathways involved in HS pathogenesis and potential biomarkers for disease severity.

Conditions

Hidradenitis Suppurativa (HS); Skin Inflammation

Keywords

Hidradenitis Suppurativa; TAAR1; JAK; STAT; SOCS; İnflammation

Outcome Measures

Primary Outcomes (1)

• Expression levels of TAAR1 and JAK/STAT pathway markers in skin tissue

  To evaluate and compare the gene and protein expression levels of TAAR1 and selected JAK/STAT pathway components in lesion and perilesion skin samples from patients diagnosed with hidradenitis suppurativa and in healthy control skin samples using molecular methods.

  At the time of molecular analysis (September 2025)

Study Arms (3)

HS lesional skin group

Lesional skin biopsy samples were obtained from patients diagnosed with hidradenitis suppurativa. All samples were collected as part of routine clinical evaluation. No treatment interventions were performed as part of the study protocol.

HS perilesional skin group

Perilesional (non-lesional) skin biopsy samples were obtained from patients diagnosed with hidradenitis suppurativa. Samples were collected from areas adjacent to active lesions during routine clinical evaluation. No procedures were performed as part of the study protocol.

Healty control skin group

Skin biopsy samples were obtained from healthy individuals without inflammatory skin disease as a control group. The samples were collected solely for comparative molecular analysis. No intervention for treatment was performed.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients aged 18 years and older with a clinical and/or histopathological diagnosis of hidradenitis suppurativa, as well as healthy control individuals aged 18 years and older without autoimmune or inflammatory disease. Healthy controls were selected to be similar to the hidradenitis suppurativa group in terms of age, sex, and metabolic characteristics. Control participants were recruited among individuals presenting for benign nevus excision at the Trakya University Medical Faculty Department of Dermatology.

You may qualify if:

• Age ≥ 18 years. Ability to read and write. For the patient group: clinical and/or histopathological diagnosis of hidradenitis suppurativa for at least 6 months.
• No use of topical treatments within the last 2 weeks, conventional systemic treatments within the last 1 month, or biologic therapies within the last 3 months prior to enrollment.
• Not pregnant at the time of enrollment. Absence of known immunosuppression or malignancy.
• For the control group: healthy individuals aged ≥18 years without any autoimmune or inflammatory disease, matched to the hidradenitis suppurativa group in terms of age, sex, and metabolic characteristics, who presented for benign nevus excision at the Trakya University Medical Faculty Department of Dermatology.

You may not qualify if:

• Presence of any autoimmune or inflammatory disease other than hidradenitis suppurativa.
• Current pregnancy. Known immunosuppression. History of malignancy. Use of topical, systemic conventional, or biologic treatments outside the defined washout periods.

Sponsors & Collaborators

• Trakya University: lead

Study Sites (1)

Trakya University Medical Faculty, Department of Dermatology

Edirne, 22030, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hidradenitis Suppurativa; Dermatitis; Inflammation

Condition Hierarchy (Ancestors)

Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration; Skin Diseases; Skin and Connective Tissue Diseases; Hidradenitis; Sweat Gland Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Yıldız Gürsel Ürün, MD

  Trakya University

  STUDY CHAIR

• Zeynep Banu Doğanlar, PhD

  Trakya University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, Dermatology Resident

Study Record Dates

• First Submitted: November 30, 2025
• First Posted: December 11, 2025
• Study Start: January 6, 2025
• Primary Completion: September 25, 2025
• Study Completion: November 21, 2025
• Last Updated: December 11, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)